How Can One Feel ‘Achchhe Din’ With High GST Rate On Ayurvedic Items, Asks Patanjali
Disappointed over high GST rate on ayurvedic products that provide "care and cure to common man at affordable price", Baba Ramdev-led Patanjali Ayurved Ltd. has asked the government as to how can people feel and live 'Achchhe Din' without the right to good health.
In a similar vein, industry body AMAM also said that while the government is aggressively promoting ayurveda globally, high tax incidence under GST will make the natural medicines costly and out of reach of the common people back home.
GST rate for classical or generic range of ayurvedic medicines must be nil and 5 percent for patented products instead of the proposed 12 percent, the Association of Manufacturers of Ayurvedic Medicines (AMAM) has said.
At present the ayurvedic medicines and products have a total tax incidence of 7 percent, including VAT, depending on the items. Under the GST regime, these items have been kept at 12 percent. "Higher GST on ayurvedic category has surprised us and is very disappointing and disheartening," Patanjali Ayurved Ltd and Patanjali Yogpeeth spokesman S K Tijarawala told PTI in an emailed response.
He further said ayurveda, which provides care and cure to common man at affordable price and is ancient and proven therapy for ages, doesn't deserve such treatment.
"Good health and healthy living is common man's basic right and expectation. Without all these, how can one feel and live 'Achchhe Din'?" he said.
Also Read: Disappointing To See High Tax On Ayurvedic Products: Dabur
Echoing similar sentiments, AMAM General Secretary Pradeep Multani said: "The Indian government has been aggressively promoting ayurvedic products internationally but what's the point of doing these things when the tax rate is so high and the common people can't afford it at home?" He further said: "This is sad and unfortunate as the Prime Minister is doing his best to boost the AYUSH system." The previous UPA government "treated ayurveda industry as step child" but this government has taken steps to take it forward, Multani said, however, adding the high tax rate proposed under GST "will make Ayurvedic, Sidha and Unani medicines out of reach of common man and kill the system".
He said if homeopathic products could be put under 5 percent slab under GST, ayurvedic products should also be kept under the rate.
Tijarawala said the world is now looking forward to Indian vedic knowledge of Ayurveda. It has created new potential of over Rs 1 lakh crore market for such natural and healthy products.
Prime Minister Narendra Modi had recently even inaugurated Patanjali Research Institute (PRI) established with outlay of over Rs 250 crore for R&D in field of Ayurved, he added.
"We have created a lead being followed by so many other companies. This has opened new avenues of self employment generation in field of herbicultutre, agriculture, ayurved practitioners, naturopathy, ayurveda product manufacturing," Tijarawala said.
Earlier, FMCG major Dabur India also expressed disappointment with the new tax structure saying it will have adverse impact on the Ayurvedic medicines category.
Also Read: GST Rates: Colas At 40%, Refrigerators At 28%, Namkeen At 12% And Condoms For Nothing
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.